Centre says cancer drug trade margin cap may cut prices by 70%
By United One News · AI-generated summary of 3 outlets' reporting
Published · Updated
AI-generated summary of the coverage listed below:
- The Centre announced that a proposed trade-margin cap could reduce the maximum retail price of anti-cancer drugs by about 20% to 70%.
- Experts warn that while this policy may lower costs for patients, it risks shifting financial burdens elsewhere in the supply chain.
- Specifically, the change could drive up expenses for hospitals and other related services.
Covered by 3 outlets across the spectrum: 0% left, 67% center, 33% right.
How each side framed it
Trade-margin cap on cancer drugs may push up costs elsewhere in supply chain: Experts
Cancer Treatment To Get Cheaper? Drug Price Caps, Hospital Markups & Patient Costs Under Scrutiny
Timeline
First to report: Deccan Herald (); 3 articles from 3 outlets so far.
Who is covering this story
- Center (2): Deccan Herald, The Hindu BusinessLine
- Right-leaning (1): India Today
Sources
- Cancer drug price caps: Balancing affordability and quality of care — Deccan Herald (center) ·
- Trade-margin cap on cancer drugs may push up costs elsewhere in supply chain: Experts — The Hindu BusinessLine (center) ·
- Cancer Treatment To Get Cheaper? Drug Price Caps, Hospital Markups & Patient Costs Under Scrutiny — India Today (right-leaning) ·